Skip to main content

Advertisement

SpringerLink
Log in

The History of Psoriatic Arthritis (PsA): From Moll and Wright to Pathway-Specific Therapy

  • Psoriatic Arthritis (J Scher, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Psoriatic arthritis is a distinct disorder, separate from rheumatoid arthritis, and first recognized in a thirteenth century Saxon skeleton. It was, however, the monumental work of Verna Wright in the 1950s that led to the acceptance by the American Rheumatism Association (now American College of Rheumatology) in 1964 as a distinct entity. Wright’s work provided the framework for a better understanding of the pathogenic mechanisms operating on this condition, and eventually led to the development of targeted therapy that has proven to be more effective and safe than conventional therapy.

Recent Findings

Pathogenesis of psoriatic arthritis has been better delineated in recent years, as well as the use of biological therapy. Recent findings are discussed in detail.

Summary

Historical aspects of psoriatic arthritis, recent developments in pathogenesis, and therapy are discussed, and the contributions of Verna Wright to our understanding of the disorder are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Baker H. Epidemiological aspects of psoriasis and arthritis. Br J Dermatol. 1966;78:249–61.

    Article  CAS  PubMed  Google Scholar 

  2. Blumberg BS, Bunnin JJ, Calkins E, et al. ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum. 1964;7:93–7.

    Article  CAS  PubMed  Google Scholar 

  3. Rogers J, Watt J, Dieppe P. Arthritis in Saxon and medioeval skeletons. Br Med J. 1981;283:1668–70.

    Article  CAS  Google Scholar 

  4. Castillo-Ojugas A, Hernandez IR. Description of psoriatic arthropathy in the 17th century. Arthritis Rheum. 1982;32:812–3.

    Article  Google Scholar 

  5. Alibert JL. Precis Theorique et Pratique sur les Maladies de la Peau. Paris: Caille et Ravier; 1818. p. 21.

    Google Scholar 

  6. Bazin P. Lecons Theoretiques et Cliniques sur les Afflections Cutanees de Nature Arthritique et Arthreux. Paris: Delahaye; 1860. p. 154–61.

    Google Scholar 

  7. Bourdillon C. Psoriasis et Arthropathies. M.D. thesis, University of Paris. 1888.

  8. Weissenback R-J. Le psoriasis arthropathique. Arch Dermatol Syph. 1938;10:13.

    Google Scholar 

  9. Vilanova X, Pinol J. Psoriasis arthropathica. Rheumatism. 1951;7:197–208.

    CAS  PubMed  Google Scholar 

  10. Coste F, Francon R, Touraine R, et al. Polyarthrite psoriasique. Rev Rhum (Mal Osteoartic). 1958;25:75–84.

    CAS  Google Scholar 

  11. Wright V. Psoriasis and arthritis. Ann Rheum Dis. 1956;15:348–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wright V. Rheumatism and psoriasis. A reevaluation. Am J Med. 1959;27:454–62.

    Article  CAS  PubMed  Google Scholar 

  13. Hench PS. Arthropathia psoriatica-presentation of a case. Proc Mayo Clin. 1927;2:89.

    Google Scholar 

  14. Romanus T. Psoriasis from a prognostic and hereditary point of view. Acta Derm Venereol (Stockh). 1945;26(Suppl 12):6.

    Google Scholar 

  15. Cats A. Psoriasis and Arthritis. Cutis. 1990;46:323–9.

    CAS  PubMed  Google Scholar 

  16. Bauer W. The diagnosis of the various arthritides. N Engl J Med. 1939;221:524–33.

    Article  Google Scholar 

  17. Bauer W, Bennett GA, Zeller JW. The pathology of joint lesions in patients with psoriasis and arthritis. Trans Assoc Am Phys. 1941;56:1941.

    Google Scholar 

  18. Whaaler F. On the occurrence of a factor on human serum actuating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand. 1940;17:172–8.

    Article  Google Scholar 

  19. Sherman MS. Psoriatic arthritis; observations on the clinical, roentgenographic, and pathological changes. J Bone Joint Surg Am. 1952;34A:831–52.

    Article  Google Scholar 

  20. Espinoza LR, Helliwell P. Psoriatic arthritis: Mary Stults Sherman, a forgotten figure in its history. Clin Rheumatol. 2014;33:1335–8.

    Article  PubMed  Google Scholar 

  21. Hench PS, Bauer W, Boland EW, et al. Rheumatism and arthritis: review of American and English literature of recent years. Part II. Ann Int Med. 1948;28:309–451.

    Article  CAS  PubMed  Google Scholar 

  22. Hench PS, Bauer W, Boland EW, et al. Rheumatism and arthritis: review of American and English literature of recent years: part I. Ann Int Med. 1948;28:66–168.

    Article  CAS  PubMed  Google Scholar 

  23. Robinson WD, Boland EW, Bunim JJ, et al. Rheumatism and arthritis: review of American and English literature in recent years: (tenth rheumatism review): part I. Ann Int Med. 1953;39:498–618.

    Article  CAS  PubMed  Google Scholar 

  24. •• Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78. Classic study of the original classification of PsA.

    Article  CAS  PubMed  Google Scholar 

  25. •• Helliwell P, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 11):ii3–8. https://doi.org/10.1136/ard.2004.032318. Original description of the CASPAR criteria for PsA.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Taylor WJ, Gladman DD, Helliwell PS, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.

    Article  PubMed  Google Scholar 

  27. Vasey FB, Espinoza LR. Psoriatic arthropathy. In: Calin A, editor. Spondyloarthropathies. Orlando: FLA. Grune & Stratton; 1984. p. 151–85.

    Google Scholar 

  28. Coates LC, Conaghan PG, Emery P, Green MJ, Ibrahim G, MacIver H, et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 2012;64:3150–5.

    Article  PubMed  Google Scholar 

  29. Fitzgerald O, Haroon M, Giles JT, Winchester R. Arthritis Res Ther. 2015;17(1):115.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. • Espinoza LR, Vasey FB, Espinoza CG, et al. Vascular changes in psoriatic synovium: a light and electromicroscopic study. Arthritis Rheum. 1982;25:677–84. First description of vascular changes in psoriatic synovium.

    Article  CAS  PubMed  Google Scholar 

  31. Candia L, Marquez J, Gonzalez C, Santos AM, Londoño J, Valle R, et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol. 2006;12:226–9.

    Article  PubMed  Google Scholar 

  32. Rose S, Dave J, Millo C, Naik HB, Siegel EL, Mehta NN. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the psoriasis atherosclerosclerosis and cardiometabolic disease initiative. Arthritis Res Ther. 2014;16(4):R161. https://doi.org/10.1186/ar4676.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Costello P, Bresnihan B, O’Farrelly C, Fitzgerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999;26:1117–24.

    CAS  PubMed  Google Scholar 

  34. Costello P, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001;166:2878–86.

    Article  CAS  PubMed  Google Scholar 

  35. Ritchlin C, Haas-Smith SA, Hicks D. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544–52.

    CAS  PubMed  Google Scholar 

  36. Canete JD, Santiago T, Cantaert T, et al. Ectopoic lymphoneogenesis in psoriatic arthritis. Ann Rheum Dis. 2007;66:720–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Veale DJ, Rogers S, Fitzgerald O. Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol. 1995;132:32–8.

    Article  CAS  PubMed  Google Scholar 

  39. Whyte HS, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch Dermatol. 1964;89:350–6.

    Article  CAS  PubMed  Google Scholar 

  40. Vasey FB, Deitz C, Fenske NA, Germain BF, Espinoza LR. Possible involvement of group a streptococci in the pathogenesis of psoriatic arthritis. J Rheumatol. 1982;9:719–22.

    CAS  PubMed  Google Scholar 

  41. Wang Q, Vasey FB, Mahfood JP, Valeriano J, Kanik KS, Anderson BE, et al. V2 regions of 16S ribosomal RNA used as a molecular marker for the species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis. Arthritis Rheum. 1999;42:2055–9.

    Article  CAS  PubMed  Google Scholar 

  42. Winchester RJ, Bernstein DH, Fischer HD, Enlow R, Solomon G. The co-occurrence of Reiter’s syndrome and acquired immunodeficiency. Ann Int Med. 1987;106:19–25.

    Article  CAS  PubMed  Google Scholar 

  43. Espinoza LR, Berman A, Vasey FB, Cahalin C, Nelson R, Germain BF. Psoriatic arthritis and acquired immunodeficiency syndrome. Arthritis Rheum. 1988;31:1034–40.

    Article  CAS  PubMed  Google Scholar 

  44. • Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheum. 2015;67:128–39. Initial description of the participation of the microbiota in PsA.

    Article  CAS  Google Scholar 

  45. Espinoza LR, Bombardier C, Gaylord SW, Lauter S, Vasey FB, Osterland CK. Histocompatibility studies in psoriasis vulgaris: family studies. J Rheumatol. 1980;7:445–52.

    CAS  PubMed  Google Scholar 

  46. Espinoza LR, Vasey FB, Oh JH, Wilkinson R, Osterland CK. Association between HLA-Bw 38 and peripheral psoriatic arthritis. Arthritis Rheum. 1978;21:72–5.

    Article  CAS  PubMed  Google Scholar 

  47. Haroom M, Winchester R, Giles JT, Hefferman E, Fitzgerald O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis. 2016;75:155–62.

    Article  CAS  Google Scholar 

  48. Alenius GM, Friberg C, Nilsson S, Wahlström J, Dahlqvist SR, Samuelsson L. Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis. J Rheumatol. 2004;31:2230–5.

    CAS  PubMed  Google Scholar 

  49. •• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Eng J Med. 2017;376:2095–6. Excellent review on PsA.

    Article  Google Scholar 

  50. • Cafaro G, McInnes IB. Psoriatic arthritis: tissue-directed inflammation? Clin Rheumatol. 2018;37:859–68. Very good review of pathogenesis of PsA.

    Article  PubMed  Google Scholar 

  51. •• Veale DJ, Fearon U. Psoriatic arthritis 1. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273–84. Excellent review of pathogenesis of PsA.

    Article  CAS  PubMed  Google Scholar 

  52. Gladman DD, Espinoza LR. International symposium on psoriatic arthritis. J Rheumatol. 1992;21:290–1.

    Google Scholar 

  53. Espinoza LR, Aguilar JL, Espinoza CG, Cuéllar ML, Scopelitis E, Silveira LH. Fibroblast function in psoriatic arthritis. I. Alteration in cell kinetics and growth factor responses. J Rheumatol. 1994;21:1502–6.

    CAS  PubMed  Google Scholar 

  54. • Espinoza LR, Aguilar JL, Espinoza CG, et al. Fibroblast function in psoriatic arthritis. II. Increased production of GF and cytokines. J Rheumatol. 1994;21:1507–11. Initial description of the role of cytokine and growth factors in PsA.

    CAS  PubMed  Google Scholar 

  55. Espinoza LR, van Solingen R, Cuellar ML, Angulo J. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci. 1998;316:271–6.

    Article  CAS  PubMed  Google Scholar 

  56. Hogan M, Sherry B, Ritchlin CT, Fabre M, Winchester R, Cerami A, et al. Differential expression of the small inducible cytokine GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. Cytokine. 1994;6:61–9.

    Article  CAS  PubMed  Google Scholar 

  57. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha and RANKL-mediated osteoclatogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gao W, Sweeney C, Walsh C, Rooney P, McCormick J, Veale DJ, et al. Notch signaling pathways mediate synovial angiogenesis in response to vascular endotghelial growth factor and angiopoietin 2. Ann Rheum Dis. 2013;72:1080–8.

    Article  CAS  PubMed  Google Scholar 

  59. Candia I, Marquez J, Hernandez C, Zea AH, Espinoza LR. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol. 2007;34:374–9.

    CAS  PubMed  Google Scholar 

  60. • Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000;356:385–90. First report on the use of biologic therapy in PsA.

    Article  CAS  PubMed  Google Scholar 

  61. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:11501157.

    Article  CAS  Google Scholar 

  62. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EHS, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89.

    Article  CAS  PubMed  Google Scholar 

  63. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–86.

    Article  CAS  PubMed  Google Scholar 

  64. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.

    Article  CAS  PubMed  Google Scholar 

  65. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–9.

    Article  CAS  PubMed  Google Scholar 

  66. Ritchlin CT, Rahman P, Kavanaugh A, McInnes I, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor thrapy: 6-month and 3-year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–9.

    Article  CAS  PubMed  Google Scholar 

  67. Thibodaux RJ, Triche M, Espinoza LR. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. Expert Opin Biol. 2018;18:821–7.

    Article  CAS  Google Scholar 

  68. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–39.

    Article  CAS  PubMed  Google Scholar 

  69. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–46.

    Article  CAS  PubMed  Google Scholar 

  70. Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomized, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.

    Article  CAS  PubMed  Google Scholar 

  71. Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of gusulkumab in patients with active psoriatic arthritis: a randomized, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213–24.

    Article  CAS  PubMed  Google Scholar 

  72. Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomized, double-blind, placebo-controlled phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550–8.

    Article  PubMed  Google Scholar 

  73. Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomized, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–73.

    Article  CAS  PubMed  Google Scholar 

  74. Mease PJ, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–50.

    Article  CAS  PubMed  Google Scholar 

  75. Den Bosch FV, Coates L. Psoriatic arthritis 2. Clinical management of psoriatic arthritis. Lancet. 2018;391:2285–94.

    Article  PubMed  Google Scholar 

  76. • Cuchacovich R, Garcia-Valladares I, Espinoza LR. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol. 2012;39:187–93. First description of the use of combination biologic therapy in PsA.

    Article  PubMed  Google Scholar 

  77. Gniadecki R, Bang B, Sand C. Combination of anti-tumor necrosis factor-α and anti-IL-12/23 antibody in refractory psoriasis and psoriatic arthritis: a long-term case series observational study. J Dermatol. 2016;174:1145–1146.

  78. Scarpa R. Personal communication.

Download references

Author information

Authors and Affiliations

  1. Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, 70112, USA

    Luis R. Espinoza

Authors
  1. Luis R. Espinoza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis R. Espinoza.

Ethics declarations

Conflict of Interest

Dr. Espinoza declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Psoriatic Arthritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Espinoza, L.R. The History of Psoriatic Arthritis (PsA): From Moll and Wright to Pathway-Specific Therapy. Curr Rheumatol Rep 20, 58 (2018). https://doi.org/10.1007/s11926-018-0771-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-018-0771-z

Keywords

Search

Navigation